The U.S. Food and Drug Administration (FDA) has requested the removal of suicide risk warnings from the labels of popular weight-loss drugs in the GLP-1 class. This step affects medications such as Wegovy by Novo Nordisk, Zepbound by Eli Lilly, and the older Saxenda from the Danish company. The agency stated it conducted additional analyses of placebo-controlled clinical trials, which concluded that there is no evidence linking GLP-1 drugs to an increased risk of suicidal thoughts or behavior. This decision expands upon the agency's previous review in 2024.
